



Morgan J Miller

Partner, Litigation Department

morganmiller@paulhastings.com

Morgan Miller is a partner in the Investigations and White Collar Defense practice at Paul Hastings and is based in the firm's Washington, D.C. and London offices. His practice focuses on representing companies and individuals in white collar defense, anticorruption, securities enforcement, and related investigations before the U.S. Securities and Exchange Commission, U.S. Department of Justice, U.K. Serious Fraud Office, and other international regulators. Mr. Miller's particular areas of expertise include cross-border investigations involving complex financial and accounting issues and anticorruption matters, including under the U.S. Foreign Corrupt Practices Act and U.K. Bribery Act, as well as internal and special committee representations, regulatory compliance, and corporate governance. Prior to joining Paul Hastings, Mr. Miller served as counsel in the Division of Enforcement at the SEC in Washington, D.C. During his tenure, Mr. Miller investigated and prosecuted a number of groundbreaking cases involving allegations of accounting fraud, insider trading, corruption, market manipulation, offering fraud, and regulated entity cases involving broker-dealers and investment advisors. Mr. Miller represents some of the largest multi-national companies and financial firms in multijurisdictional investigations—leading investigations in more than 40 countries throughout Africa, Asia, Europe, the Middle East, and South America. Many of these matters involve parallel investigations by the US, UK, and other international authorities. On a proactive basis, Mr. Miller regularly conducts risk assessments, transactional due diligence, and enhancements to global compliance programs. Mr. Miller's experience spans a number of industries, including financial services, life sciences, technology, oil and gas, and defense. Mr. Miller is particularly experienced in the pharmaceutical and medical device sectors, representing multi-national companies in some of the most significant cases under the FCPA and the UK Bribery Act.

Washington, D.C.

T: 1(202) 551-1861

F: 1(202) 551-0261

London

T: 44-020-3321-1029

Practice Areas

Life Sciences and Healthcare
Anti-corruption and FCPA
Investigations and White
Collar Defense
Securities Enforcement
Securities Litigation
Litigation

Admissions

District of Columbia Bar
California Bar

Education

University of California, San
Diego, B.A. 1994
University of San Diego,
School of Law, J.D. 1999

Recent Representations

- Representing a large multinational company in connection with an SEC

Morgan J Miller (Continued)

monitorship, including with respect to related enhancements to its global compliance program.

- Representing a Fortune 50 pharmaceutical and healthcare company in connection with anti-corruption investigations by the DOJ, SEC, UK Serious Fraud Office, and other government authorities involving over three dozen countries across the globe.
- Representing a multi-national pharmaceutical company in connection with its global anti-corruption/ FCPA due diligence associated with its US\$16 billion acquisition of the vaccines business of another pharmaceutical company, divestiture of its oncology business, and a consumer healthcare joint venture.
- Advising a Fortune 50 life sciences company in connection with corporate governance and enhancements to its global compliance program, including a global risk assessment, third-party training, internal audit program, and third-party oversight.
- Representing a global specialist HIV company in conducting internal investigations of anti-corruption allegations in several countries, including in the CIS, Middle East, and South America.
- Representing a foreign sovereign wealth fund in an investigation of certain trading activities by the SEC. The SEC declined to take enforcement action following a lengthy investigation.
- Representing a Fortune 50 medical device company in anti-corruption investigations by the SEC and Italian authorities. The SEC declined to institute enforcement action.
- Representing a major investment bank in an investigation by the SEC and state regulators regarding mortgage and securities-related issues.
- Advising a Fortune 50 company on anti-corruption matters in China, including with respect to a joint venture and third-party sales force.
- Defending a global oil and gas corporation in the successful resolution of investigations by the DOJ and SEC regarding possible FCPA violations in its Nigerian operations.
- Representing a global manufacturer in FCPA investigations by the SEC, including conducting internal investigations in China and Europe while developing a global risk assessment. The matter favorably resolved with the SEC, which credited the Company's response and remediation of the issues.
- Counseling a private equity fund regarding compliance and due diligence matters in the Middle East.
- Conducting an internal investigation of financial reporting issues for a national clothing manufacturer.
- Advising the audit committee of a major animal products company in conducting investigations of financial reporting, executive perquisites, and

Morgan J Miller (Continued)

potential conflicts of interest.

- Representing a CFO of a life sciences company in an investigation by the SEC regarding financial reporting. The SEC declined to take enforcement action.
- Developing a global compliance program for a multi-national technology company.
- Representing the former CFO of a NASDAQ-listed corporation in SEC and DOJ investigations concerning allegations of accounting fraud. Investigations concluded without any criminal charges or SEC enforcement proceedings.
- Representing numerous other notable companies and executives in life sciences, technology, retail, telecommunications, and manufacturing companies in investigations by the SEC regarding financial reporting, accounting, executive compensation, and insider trading matters.
- Conducting numerous internal investigations on behalf of corporations and their Audit Committees concerning accounting, revenue recognition, disclosure, and various other securities-related issues.
- Representing life sciences, technology, and financial institutions and their officers and directors in shareholder class actions, derivative lawsuits, and other commercial litigation, including Capital One Financial, Northwestern Corporation, Dura Pharmaceuticals, Ligand Pharmaceuticals, and Semtech Corporation, among others.

Accolades and Recognitions

- Mr. Miller has been recognized for his innovative approach to complex investigations and significant litigation. One major corporation's litigation team recently awarded Mr. Miller as its first ever "Hero of the Year" recipient for his outstanding representation in a high-profile FCPA investigation.
- Ethisphere 2014, "Attorneys Who Matter," Specialists – Private Practice
- Global Investigations Review 2016, "Washington DC's Leading FCPA Practices"
- Recipient of the 2014 Burton Award for Distinguished Legal Writing

Speaking Engagements and Publications

- Mr. Miller lectures and publishes regularly and is often quoted in articles on securities enforcement, anti-corruption, and legal ethics issues published by Bloomberg, Ethisphere, Law360, Los Angeles Times, Main Justice, Reuters, and the Wall Street Journal, among other leading publications.
- Co-Author of the Bloomberg/BNA treatise, Responding to Corporate Criminal Investigations.
- Contributing author of the Global Law and Business treatise, Anti-corruption Laws and Regulations (United Kingdom).

Morgan J Miller (Continued)

Education

- University of San Diego School of Law, J.D., Order of the Coif, 1999
- University of California, San Diego, B.A., 1994

News

May 29, 2020

Paul Hastings Wins National Law Journal's Washington, D.C. White Collar Litigation Department of the Year Award

October 31, 2017

Paul Hastings Investigations and White Collar Defense Practice Named Most Impressive Investigations Practice by Leading Industry Publication Global Investigations Review

June 05, 2013

Paul Hastings Extensive Practice Strength Highlighted in The Legal 500 United States 2013

Insights

July 08, 2020

Evolution not Revolution: DOJ and SEC Update The FCPA Resource Guide

April 13, 2020

PH COVID-19 Client Alert Series: Rethinking Approaches to Detecting and Investigating for Life Sciences Companies

March 17, 2020

PH COVID-19 Client Alert Series: Issues for Private Fund Managers in the Age of COVID-19

January 23, 2020

What the SFO Looks For in a Compliance Programme—New Guidance Published January 2020

November 14, 2019

Delayed Consequences—Mexico Seeks Damages Long After FCPA Resolution

Morgan J Miller (Continued)

August 13, 2019

New UK Serious Fraud Office Co-operation Guidance: From Avoiding “Trampled Crime Scenes” to Helping Secure Admissible Evidence

December 05, 2016

Latin America’s Headline: Anti-Corruption

October 21, 2016

Winter Is Coming: Responding to a Chilling Enforcement Landscape in Russia

December 21, 2015

Hedge Fund Report: Summary of Key Developments - Fall 2015

June 01, 2015

Hedge Fund Report - Summary of Key Developments - Spring 2015

December 23, 2014

Hedge Fund Report—Summary of Key Developments—Fall 2014

May 16, 2014

Hedge Fund Report - Summary of Key Developments - Spring 2014

May 16, 2014

What are the most significant issues for global companies in managing their exposure to U.S. regulatory risk and ensuring compliance with the Foreign Corrupt Practices Act?

October 09, 2013

Hedge Fund Report: Summary of Key Developments - Fall 2015

May 29, 2013

FCPA Declinations - How to Maximize Your Chance to Get a Pass When a Corruption Problem Occurs

April 29, 2013

Responding to Corporate Criminal Investigations

April 25, 2013

Hedge Fund Report - Summary of Key Developments - Spring 2013

March 11, 2013

Morgan J Miller (Continued)

US High Court Decision Will Hasten SEC Enforcement Actions

February 07, 2013

Quarterly FCPA Report: Fourth Quarter 2012

December 05, 2012

Hedge Fund Report - Summary of Key Developments - Fall 2012

August 27, 2012

Lessons Learned from Pfizers Settlement of FCPA Claims

December 19, 2011

SEC Enforcement Division completes most productive year in its history

April 29, 2011

The U.S. Government's Recent Efforts to Ban Pharmaceutical Executives from the Industry Without Due Process

April 27, 2011

Extraterritorial Effect of the Anti-Corruption Law of the Peoples Republic of China

April 25, 2011

Hedge Fund Report Summary of Key Developments - Spring 2011

March 30, 2011

UK Bribery Act Guidance Part 1: Guidance Overview

January 31, 2011

SEC Adopts First of ABS Disclosure Regulations

December 20, 2010

Comments on the Whistleblower Program of the Dodd-Frank Act

October 29, 2010

Hedge Fund Report Summary of Key Developments Fall 2010

October 06, 2010

China Matters: Technology Companies Operating in Asia Remain a Focus for FCPA Enforcement

September 16, 2010

Morgan J Miller (Continued)

Dodd-Frank Act Provides Rewards for Whistleblowers Who Report FCPA Violations

July 06, 2010

District Court Holds That Rule 10b-5 Insider Trading Provisions Apply to Credit Default Swap (CDS) Contracts

June 25, 2010

The Supreme Court Limits the Scope of the Federal Criminal Honest Services Fraud Statute to Conduct Involving Bribes or Kickbacks

June 25, 2010

Supreme Court Affirms Dismissal of F-Cubed Class Action and Holds That There is No Extraterritorial Application of Section 10(b)

April 23, 2010

Double Teamed: Defending Parallel Investigations Under SECs New Cooperation Initiative

Published by the Washington Legal Foundation's Legal Backgrounder (April 2010)

April 07, 2010

SEC Unveils Specialized Units and New Cooperation Standards

January 20, 2010

SEC Unveils Specialized Units and New Cooperation Standards

November 19, 2009

Summary of 2009 Hedge Fund Key Developments: Litigation and Enforcement

January 27, 2009

Senators Propose SAFE Funds to Dramatically Increase Enforcement Staffs of the Securities and Exchange Commission and Department of Justice

November 28, 2008

The SEC Sheds Light on Enforcement Procedures. The Daily Journal

September 24, 2008

NYAG and SEC Announce Wide-Ranging Market Manipulation Probes; SEC Adopts New Rules to Combat Abusive Short Selling

Morgan J Miller (Continued)

January 14, 2008

Restating Financials? Forfeiting Bonuses and Profits to the SEC Now a Real Threat

December 04, 2007

The SEC Targets 10b5-1 Plans Ten Things Executives and Boards Should Be Doing

January 12, 2006

SEC Sets Standards For Imposing Corporate Penalties

May 01, 2003

California Supreme Court Expands Securities Fraud Class Action Plaintiffs to Include Stock Holders

Rankings & Awards

May 27, 2020

Recognized as the National Law Journal's Washington, D.C. White Collar Litigation Department of the Year

October 24, 2019

Recognized in the Global Investigations Review's GIR 100 for 2019

November 02, 2018

Recognized in the Global Investigations Review's GIR 100 for 2018

October 27, 2017

Recognized in the Global Investigations Review's GIR 100 for 2017

August 22, 2016

Ranked by Global Investigations Review's coverage of Washington DC's FCPA Bar

April 30, 2014

Winner of 2014 Burton Award for Distinguished Legal Writing